Company / EPS (Diluted)
Olema Pharmaceuticals, Inc. EPS (Diluted) History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.20
FY2024
5-year range
-$3.42 / -$1.80
FY2020-FY2024
Trend
-2.8%
vs FY2023
Sector context
#133 of 204
Health Care
What the data says
At $-2.20, Olema Pharmaceuticals, Inc.'s eps (diluted) ranks #133 of 204 in the Health Care sector. EPS (Diluted) has fluctuated over the past 6 years, ranging from $-3.42 in FY2020 to $-1.66 in FY2019.
Based on SEC 10-K filings.
-2.20 in FY2024.
Improved from $-2.62 to $-2.20 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#133 of 204 in Health CareTop 65% of 204This company -$2.20 Sector average -$0.89
▼
-148.2% below sector average
Key checks
Key Insights
- In FY2024, eps (diluted) decreased 2.8% year-over-year.
- Ranks #133 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2019.
- Lowest eps (diluted) in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$2.20 | -2.8% |
| FY2023 | -$2.14 | +18.3% |
| FY2022 | -$2.62 | -45.6% |
| FY2021 | -$1.80 | +47.4% |
| FY2020 | -$3.42 | -106.0% |
| FY2019 | -$1.66 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026